New in October 2026 for skincare and acne is retail access to Epiduo Gel and new long-term data on oral denifanstat. Benzene lawsuits over benzoyl peroxide were dismissed, and an mRNA acne vaccine remains in early trials.
Epiduo Gel pairs adapalene, a retinoid that unclogs pores, with benzoyl peroxide, which lowers acne bacteria. Denifanstat is a once-daily pill that blocks fatty-acid synthase, an enzyme tied to sebum production. Here is what each change means for treatment choices this fall.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Check eligibility on Globenewswire’s official study page — Use this page to check the study’s participation requirements.
- Read the official notice from Galderma — Use this primary source to verify the official announcement.
Table of Contents
- Can you buy Epiduo without a prescription now?
- How did oral denifanstat perform over one year?
- Should you keep using benzoyl peroxide?
- Will a vaccine replace acne creams soon?
Can you buy Epiduo without a prescription now?
Yes for many teens and adults. According to Galderma in the Galderma approval notice, Differin Epiduo Gel with adapalene 0.1% plus benzoyl peroxide 2.5% received FDA approval for over-the-counter use in ages 12 and older with acne vulgaris. The switch moves prescription-strength combination therapy to retail without a prescription.
The change matters when a single product fits the routine. Check these points before you shop: Start with the drug facts label for frequency, amount, sun protection, and moisturizer use. Stop and ask a pharmacist or dermatologist about burning, swelling, or spreading irritation.
- age 12 or older with acne vulgaris, the common form with clogged pores and pimples
- need for a fixed adapalene plus benzoyl peroxide combination rather than separate products
- no prior intolerance to retinoids or benzoyl peroxide that needs clinician input
How did oral denifanstat perform over one year?
Dermatology Times reported in its October 1 results summary that once-daily denifanstat reached 56.7% treatment success and 71.8% mean total-lesion reduction through up to 52 weeks. The results came from phase 3 extension ASC40-304 in moderate-to-severe acne. The pattern favors steady control rather than a fast short course. Context limits direct use in the United States. The 52-week data came from an open-label extension in China run by Ascletis and presented at EADV Vienna Sept. 30-Oct. 3, 2026, with no discontinuations for adverse events reported, according to the Sagimet and Ascletis press release.
The drug is not FDA-approved, and U.S. Phase 3 AURORA screening was expected in Oct. 2026. Sagimet Biosciences said in August 2026 that it received FDA IND clearance and a Study May Proceed letter to start U.S. Phase 3 testing in adolescent and adult acne patients. That step affects future options, not current prescriptions. Readers who want trial access can ask a dermatologist about eligibility once sites open.
Should you keep using benzoyl peroxide?
Yes, with normal purchase and storage habits. BeautyMatter reporting on the SDNY decision in its September court report says a federal judge dismissed with prejudice on Sept. 15, 2026 a consolidated class action over CeraVe and La Roche-Posay benzoyl peroxide products. The ruling held that FDA's acne monograph preempts state claims and requires no benzene warning.
A LawCommentary summary of the FDA position in its September FDA summary says FDA testing found over 90% of benzoyl peroxide products had undetectable or very low benzene. FDA recalled only over-limit lots and estimated very low cancer risk even with decades of daily use. The agency also acknowledged that benzoyl peroxide can degrade to benzene in heat. Heat control is the practical point. Keep tubes and washes in a cool, dry place, avoid hot cars and radiators, close caps tightly, and discard expired or swollen tubes.
Will a vaccine replace acne creams soon?
No. Sanofi is in early clinical trials of an experimental mRNA acne vaccine, according to Dermatology Times acne coverage in 2026. The approach targets the inflammatory response rather than symptoms alone. Dermatologists describe it as prevention-oriented but unproven and years from availability.
That timeline keeps daily care central. Retinoids, benzoyl peroxide, and prescribed oral treatments remain the proven paths for persistent or scarring acne. Early vaccine trials test safety and immune response first, then dose, durability, and effect across acne types. Track trial news through dermatology sources and ask your clinician about evidence-based adjustments at your next visit.